DongKook Life Science pursues name change to 'DK Luonics'…expands new drug and CMO business
Predicted impact: Low
Name change to DK Luonics already reported with shareholder meeting notice
DongKook Life Science동국생명과학
303810 · KOSDAQ · ₩303810 · 동국생명과학
₩2,280 ₩0 (0.00%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −40.86%
- Market cap
- ₩73B
- Enterprise value
- ₩67B
- P/E
- 14.8×
- P/B
- 0.5×
- Dividend yield
- 0.0%
- ROE
- 3.7%
- Net margin
- 4.2%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−44.5% from the high
₩2,155Today: ₩2,250 – ₩2,335₩4,110
Returns
- 1W−9.5%
- 1M−18.6%
- 3M−2.8%
- 6M−34.7%
- YTD−37.7%
- 1Y−40.9%
- Volume today
- 140,872
- 0.0× the 20-day average
- Traded today
- ₩323M
- Listed shares
- 31,984,140
- EPS (12 months)
- ₩154
- Earnings yield 6.7%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 28 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Reports describe a rebrand and business expansion toward global markets, with no clear negative or positive financial results. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-24.9% over the last month; the price is below its 20-day average.
- News impactLow4 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
DongKook Life Science stock overview
DongKook Life Science (동국생명과학, KRX: 303810) is listed on KOSDAQ, in the Biotech & Pharma sector. Dongkook Pharmaceutical's sister business Dongkook Life Science is a Korean contrast agent specialist that makes injectable X-ray, CT, MRI and interventional imaging contrast media used in hospitals. Its shares closed at ₩2,280 on Oct 27, 2026, unchanged on the day, giving it a market value of ₩73B.
Key facts
- Market cap
- ₩73B
- Sector
- Biotech & Pharma
- Latest price change
- 0.00%
- As of
- Oct 27, 2026
- Main business
- Dongkook Pharmaceutical's sister business Dongkook Life Science is a Korean contrast agent specialist that makes injectable X-ray, CT, MRI and interventional imaging contrast media used in hospitals.
Quick answers about DongKook Life Science
- What does DongKook Life Science do?
- Dongkook Pharmaceutical's sister business Dongkook Life Science is a Korean contrast agent specialist that makes injectable X-ray, CT, MRI and interventional imaging contrast media used in hospitals. Its product lines include iodinated contrast agents such as Pamiray, Mediray and Duoray, the MRI agents Uniray and Gadovision, and the lipiodol generic Fattiodol. The company also imports and distributes imaging equipment such as CT, MRI, mammography and ultrasound systems from overseas manufacturers, and sells to hospitals in Korea and exports to partners in about 25 countries.
- What is the market cap of DongKook Life Science?
- The market capitalisation of DongKook Life Science was ₩73B at the close on Oct 27, 2026.
- Who are the largest shareholders of DongKook Life Science?
- According to the latest official filings, the largest reported holders are Dongkook Pharmaceutical (39.50%, as of Aug 19, 2025); Kwon Ki-beom (11.11%, as of Aug 19, 2025); Life Value-Up Private Equity Fund (4.52%, as of Dec 10, 2025).
- When is the next earnings report from DongKook Life Science?
- Korean companies rarely announce results dates in advance. Based on when DongKook Life Science filed the same report in past years, its next 3q results is expected around Nov 13, 2026.
Company profile
Dongkook Pharmaceutical's sister business Dongkook Life Science is a Korean contrast agent specialist that makes injectable X-ray, CT, MRI and interventional imaging contrast media used in hospitals. Its product lines include iodinated contrast agents such as Pamiray, Mediray and Duoray, the MRI agents Uniray and Gadovision, and the lipiodol generic Fattiodol. The company also imports and distributes imaging equipment such as CT, MRI, mammography and ultrasound systems from overseas manufacturers, and sells to hospitals in Korea and exports to partners in about 25 countries.
Written by AI from the company's latest annual report.
- Korean name
- 동국생명과학
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 박재원
- Founded
- May 2017
- Listed
- Feb 2025
- Listed shares
- 31,984,140
- Fiscal year ends
- Month 12
- Website
- dkls.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
DongKook Life Science Pursues Name Change to DK Luonix…"Targeting Global Markets"
Predicted impact: Low
Proposed company name change is a routine corporate housekeeping item with no financial size given.
Recent filings
See all- Determination of Shareholder Register Closure Period or Record DateOct 26, 2026
- Shareholders' meeting calledOct 26, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Insider shareholding reportJul 2, 2026
- Quarterly report (Mar 2026)May 14, 2026
Titles in Korean until English translations are added.
Also known as: DongKook Life Science / 동국생명과학 / 303810 / KRX:303810
Source: KRX statistical information